VENTYX BIOSCIENCES INC. - COMMON STOCK

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

14 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

12 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress

07 Nov 2024 16:05:01 By Nasdaq GlobeNewswire

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024

15 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi

23 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease

06 Sep 2024 08:00:11 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Departure of Chief Financial Officer

30 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

28 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

08 Aug 2024 16:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn’s Disease

29 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

16 May 2024 16:05:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

16 May 2024 08:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

09 May 2024 16:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

02 May 2024 16:05:01 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event

11 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Announces $100 Million Private Placement of Common Stock

07 Mar 2024 08:00:19 By Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

06 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024

04 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress

27 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)

22 Feb 2024 07:00:00 By Nasdaq GlobeNewswire